CDK4 and breast carcinoma: Inhibitors targeting CDK4/6, as palbociclib, ribociclib, and abemaciclib offer both hope and challenges for the treatment of breast cancer (Besson et al., 2008; Bai et al., 2023; Wu et al., 2022).